1. Home
  2. AGIO vs CASH Comparison

AGIO vs CASH Comparison

Compare AGIO & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$28.92

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Pathward Financial Inc.

CASH

Pathward Financial Inc.

HOLD

Current Price

$74.22

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
CASH
Founded
2007
1954
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
AGIO
CASH
Price
$28.92
$74.22
Analyst Decision
Buy
Buy
Analyst Count
8
2
Target Price
$32.13
$91.00
AVG Volume (30 Days)
1.5M
246.4K
Earning Date
02-12-2026
01-20-2026
Dividend Yield
N/A
0.27%
EPS Growth
N/A
9.29
EPS
N/A
7.87
Revenue
$44,791,000.00
$780,120,000.00
Revenue This Year
$28.75
$10.95
Revenue Next Year
$139.45
$4.75
P/E Ratio
N/A
$9.38
Revenue Growth
36.26
5.66
52 Week Low
$22.24
$64.45
52 Week High
$46.00
$86.00

Technical Indicators

Market Signals
Indicator
AGIO
CASH
Relative Strength Index (RSI) 50.24 56.48
Support Level $24.16 $72.63
Resistance Level $27.95 $76.39
Average True Range (ATR) 1.20 1.79
MACD 0.50 -0.04
Stochastic Oscillator 82.82 46.82

Price Performance

Historical Comparison
AGIO
CASH

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

Share on Social Networks: